|Bid||93.88 x 373700|
|Ask||94.00 x 1281100|
|Day's Range||93.64 - 94.52|
|52 Week Range||72.96 - 94.52|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||27.63|
|Earnings Date||Jan 23, 2018 - Jan 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.59|
Canopy Growth’s bid for rival cannabis company Acreage Holdings was a $3.4bn bet on cannabis becoming legal across the US as soon as next year, the chief executives of the two companies have said. , in which Ontario-based Canopy will pay New York-headquartered Acreage just $300m in cash upfront, depends on federal legalisation in the US. “We believe it takes place sooner than others anticipate — I’m going to call within the next 12 months, 18 months on the far side,” Kevin Murphy, Acreage’s chairman and chief executive, told the Financial Times.
Notices urge a clear-out ahead of our return to our former headquarters, Bracken House, near St Paul’s Cathedral. Lex’s desks, it must be said, are among the less cluttered. Lex was sceptical about the projections in the IPO prospectus published by the ride-hailing business in preparation for next month’s listing.
Based on Novartis AG's (VTX:NOVN) earnings update in December 2018, analyst consensus outlook appear pessimistic, with profits p...
The Tokyo Stock Exchange Mothers Index of growing companies has jumped 21 percent from a low on Christmas Day, outpacing a 14 percent advance for the Nikkei 225 Stock Average. The Jasdaq Index, comprised of 712 mostly smaller companies, is also up 21 percent. One is smaller companies are often less dependent on exports, and therefore more resilient to external factors such as the trade war and sputtering global economy, according to Tetsuo Seshimo, a fund manager at Saison Asset Management Co. in Tokyo.
Attractive stocks have exceptional fundamentals. In the case of Novartis AG (VTX:NOVN), there's is a highly-regarded dividend-paying company with a a great track record of delivering benchmark-beating performance. In theRead More...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! This article is for investors who would like to improveRead More...
(Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of ...
Drug companies have spent big on chimeric antigen receptor T-cells, or CAR-T, cancer therapies. The treatment involves a process whereby a patient’s T-cells are extracted, modified and reinserted into the body to fight cancer. The treatments are exciting from a scientific point of view and have provided significant clinical benefits to a small number of patients with severe and uncommon forms of cancer.
Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines..
Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines.
Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland's 20 largest listed companies, market operator SIX said on Tuesday. Information about any other changes to SMI and Switzerland's other indexes will be released later, the bourse said. Novartis last year announced the spin off of Alcon to the Basel drugmaker's shareholders in the first half of this year.
Novartis AG (NOVN.EB) plans to stand firm on the pricing of a cancer drug in the Netherlands despite accusations that it has abused orphan-drug rules to sharply raise the cost of the treatment, as the debate on drug pricing flares up on both sides of the Atlantic. The healthcare giant has attracted criticism in the Netherlands for charging 92,000 euros ($106,000) per patient for a four-dose course of the drug, Lutathera, despite the treatment already being made for years by Dutch hospital pharmacies at a cost of EUR16,000, according to the Dutch health ministry.
The biotech world is feverishly awaiting the FDA's potential approval of a gene therapy called Zolgensma, a spinal muscular atrophy treatment, that is expected from Novartis in May.
Novartis AG (NVS) reported fourth-quarter results before the opening bell on Wednesday. Warning! GuruFocus has detected 2 Warning Sign with NVS. By segment, sales in the innovative medicines business increased 5.4% year over year to $9.022 billion, sales from the Sandoz division fell 5.2% from the prior-year quarter to $2.459 billion and Alcon sales rose 1.5% to $1.788 billion.
Novartis earnings and sales lagged expectations early Wednesday, as the drug giant guided to low- to mid-single digit sales growth in 2019. Novartis stock was down on the news.
Drug companies may be raising list prices in the U.S., but discounts mean the actual price of many drugs is falling. AG on Wednesday said net prices—the sum it gets after discounts to the list price—slipped last year and would continue to fall in 2019. Although drug companies are still raising list prices, they are under growing political pressure to limit those increases.
McDonald’s, Boeing, Novartis, Southwest Airlines and Foxconn are the companies to watch.